Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:10:27 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Bioservo - Commercialization progress

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Bioservo - Commercialization progress

2023-04-25 11:20:00

Redeye saw results that did not represent a significant deviation from the expectations. The sales were up 58%, with costs trending downward. The deliveries of Carbonhand have started, and interest looks pretty high from different stakeholders. The earlier-than-expected US progress with the FDA registration is a clear positive. We only change our estimates slightly: however, the financing need adds another share issue of SEK 30 m, creating a dilution effect. We lower our Base case to SEK 3.3 per share from SEK 5 per share.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/